Advancing Pharmacoequity in Low‐ and Middle‐Income Countries via Model Informed Drug Development
Across low- and middle-income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model-informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake. Physiologically based and population pharmacokinetic modeling can strengthen regulatory review and optimize dosing. When aligned with global harmonization initiatives, these tools can support evidence-based decisions and advance pharmacoequity by ensuring context-appropriate therapies reach patients.
Authors
- Thaddeus H. Grasela
- Ian S. Haworth (ORCID: https://orcid.org/0000-0002-3873-0899)
- Catriona John Waitt (ORCID: https://orcid.org/0000-0003-0134-5855)
- Sandra Cvijić (ORCID: https://orcid.org/0000-0001-8291-791X)
- Francis Williams Ojara (ORCID: https://orcid.org/0000-0002-6425-6828)
- Henry Enzama (ORCID: https://orcid.org/0009-0000-1901-9404)
Institutions
- University of Southern California (US)
- Gulu University (UG)
- University of Liverpool (GB)
- University of Belgrade (RS)
- Liverpool Women's Hospital (GB)
- Infectious Diseases Institute (UG)
- Calspan-University of Buffalo Research Center (US)
- Makerere University (UG)
Publication Details
- Journal
- Clinical and Translational Science
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1111/cts.70571
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00